In this review:
Venous thromboembolism risk: tofacitinib vs TNF inhibitors
Smoking cessation and risk of seropositive RA
Moderate or high disease activity escalates RA therapy?
Upadacitinib vs placebo and adalimumab in RA
PET/CT for giant cell arteritis
Statin use and disease activity in AS
Plasma exchange and reduceddose glucocorticoids in ANCAassociated vasculitis
Serum urate target and elevated mortality in gout
Genetic risk score prediction in AS
Subcutaneous tanezumab for OA
Please login below to download this issue (PDF)